Total medical devices industry venture financing deals in Q1 2019 worth $2.06bn were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 10.1% over the previous quarter and a drop of 11.6% when compared with the last four-quarter average, which stood at $2.33bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $1.45bn. At the country level, the US topped the list in terms of deal value at $1.43bn.
In terms of volumes, North America emerged as the top region for medical devices industry venture financing deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of venture financing deals activity in Q1 2019 was the US with 148 deals, followed by China with 16 and Israel with eight.
In 2019, as of the end of Q1 2019, medical devices venture financing deals worth $2.06bn were announced globally, marking a decrease of 22.8% year on year.
Medical devices industry venture financing deals in Q1 2019: Top deals
The top five medical devices industry venture financing deals accounted for 20.9% of the overall value during Q1 2019.
The combined value of the top five medical devices industry venture financing deals stood at $431m, against the overall value of $2.06bn recorded for the quarter. The top announced medical devices industry venture financing deal tracked by GlobalData in Q1 2019 was CICC Capital Management, IDG Capital, LB Investment, Meinian Onehealth Healthcare (Group), Ping An Insurance, Samsung Ventures Investment and Tasly Pharmaceutical Group’s $100m venture financing of Hangzhou KangSheng Health Management Consulting.
In second place was the $100m venture financing of Health Catalyst Systems by Kaiser Permanente Ventures, Norwest Venture Partners XII, Orbimed Advisors, Sands Capital Ventures, Sequoia Capital Operations and UPMC Enterprises and in third place was Advanced Technology Ventures, Endeavour Vision, LSV Capital Management, Morgenthaler Ventures, Qiming Venture Partners USA, Richard King Mellon Foundation, Split Rock Partners, USVP Management, Versant Venture Management, Vertex Venture Holdings and Windham Venture Partners’ $79m venture financing of Nuvaira.
The $77m venture financing of Ablative Solutions by BioStar Ventures, Michigan Accelerator Fund I and Novus Biotechnology Fund 1 and Abingworth Management, Advanced Technology Ventures, Bain Capital Life Sciences, Correlation Ventures, Endeavour Vision, HBM Partners, HealthCrest, Hercules Capital and Interwest Partners’ venture financing of Gynesonics for $75m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.